
Keywords: آنژیوتانسین تبدیل آنزیم; Clinical trial; Pilot; Training concept; Pharmacokinetic; Pharmacodynamic; Feasibility; ACE; Angiotensin-converting-enzyme; Cmax; maximum serum concentration; ELISA; Enzyme-linked immunosorbent assay; EMA; European Medicines Agency; EU; European Union; FD